| Primary |
| In Vitro Fertilisation |
30.0% |
| Infertility |
28.8% |
| Assisted Fertilisation |
12.5% |
| Prevention Of Premature Ovulation |
10.0% |
| Ovulation Induction |
6.3% |
| Product Used For Unknown Indication |
6.3% |
| Anovulatory Cycle |
2.5% |
| Blood Luteinising Hormone Abnormal |
2.5% |
| Prophylaxis |
1.3% |
|
| Drug Ineffective |
15.1% |
| Needle Issue |
13.2% |
| No Adverse Event |
11.3% |
| Product Quality Issue |
7.5% |
| Injection Site Urticaria |
5.7% |
| Underdose |
5.7% |
| Anaphylactic Reaction |
3.8% |
| Ectopic Pregnancy |
3.8% |
| Low Birth Weight Baby |
3.8% |
| Maternal Exposure During Pregnancy |
3.8% |
| Ovarian Hyperstimulation Syndrome |
3.8% |
| Respiratory Distress |
3.8% |
| Skin Irritation |
3.8% |
| Treatment Noncompliance |
3.8% |
| Abortion Missed |
1.9% |
| Air Embolism |
1.9% |
| Anaphylactic Shock |
1.9% |
| Blood Human Chorionic Gonadotropin Increased |
1.9% |
| Caesarean Section |
1.9% |
| Cardiovascular Insufficiency |
1.9% |
|
| Secondary |
| In Vitro Fertilisation |
24.0% |
| Infertility |
17.3% |
| Product Used For Unknown Indication |
15.1% |
| Ill-defined Disorder |
14.0% |
| Ovulation Induction |
10.6% |
| Ovarian Hyperstimulation Syndrome |
5.0% |
| Anaesthesia |
2.2% |
| Assisted Fertilisation |
1.7% |
| Prophylaxis |
1.7% |
| Hormone Suppression Therapy |
1.1% |
| Luteal Phase Deficiency |
1.1% |
| Oocyte Donation |
1.1% |
| Ovarian Hyperfunction |
1.1% |
| Routine Health Maintenance |
1.1% |
| Constipation |
0.6% |
| Infertility Female |
0.6% |
| Pregnancy |
0.6% |
| Prevention Of Premature Ovulation |
0.6% |
| Vitamin Supplementation |
0.6% |
|
| Ectopic Pregnancy |
31.1% |
| Ovarian Hyperstimulation Syndrome |
15.6% |
| Deep Vein Thrombosis |
8.9% |
| Cytogenetic Abnormality |
4.4% |
| Eosinophilic Pneumonia Acute |
4.4% |
| Hypoxia |
4.4% |
| Abdominal Pain |
2.2% |
| Abortion Induced |
2.2% |
| Abortion Spontaneous |
2.2% |
| Drug Ineffective |
2.2% |
| Dyspnoea |
2.2% |
| Effusion |
2.2% |
| Emotional Disorder |
2.2% |
| Feeling Abnormal |
2.2% |
| Genital Herpes |
2.2% |
| Hyponatraemia |
2.2% |
| Limb Discomfort |
2.2% |
| Low Density Lipoprotein Increased |
2.2% |
| Maternal Exposure Before Pregnancy |
2.2% |
| Metrorrhagia |
2.2% |
|
| Concomitant |
| In Vitro Fertilisation |
28.9% |
| Product Used For Unknown Indication |
20.7% |
| Assisted Fertilisation |
6.6% |
| Ovarian Disorder |
6.6% |
| Ovarian Hyperstimulation Syndrome |
4.1% |
| Drug Use For Unknown Indication |
3.3% |
| Ovulation Induction |
3.3% |
| Supplementation Therapy |
3.3% |
| Vitamin Supplementation |
3.3% |
| Thyroid Disorder |
2.5% |
| Vitamin D Deficiency |
2.5% |
| Blood Follicle Stimulating Hormone Abnormal |
1.7% |
| Gastrooesophageal Reflux Disease |
1.7% |
| Mineral Supplementation |
1.7% |
| Oestrogen Replacement Therapy |
1.7% |
| Polycystic Ovaries |
1.7% |
| Premenstrual Syndrome |
1.7% |
| Prophylaxis |
1.7% |
| Sedative Therapy |
1.7% |
| Superovulation |
1.7% |
|
| Ovarian Hyperstimulation Syndrome |
21.2% |
| Premature Baby |
9.1% |
| Antepartum Haemorrhage |
6.1% |
| Emotional Distress |
6.1% |
| Rectal Tenesmus |
6.1% |
| Thinking Abnormal |
6.1% |
| Twin Pregnancy |
6.1% |
| Aspartate Aminotransferase Increased |
3.0% |
| Cholelithiasis |
3.0% |
| Dizziness |
3.0% |
| Drug Exposure During Pregnancy |
3.0% |
| Hypoaesthesia |
3.0% |
| Liver Function Test Abnormal |
3.0% |
| Mental Disorder |
3.0% |
| Mood Altered |
3.0% |
| Oestradiol Decreased |
3.0% |
| Off Label Use |
3.0% |
| Pleural Effusion |
3.0% |
| Pregnancy |
3.0% |
| Pregnancy Test Positive |
3.0% |
|
